HALO
Halozyme Therapeutics Inc.

4,876
Mkt Cap
$7.66B
Volume
3.26M
52W High
$79.50
52W Low
$46.26
PE Ratio
14.16
HALO Fundamentals
Price
$67.35
Prev Close
$65.11
Open
$65.28
50D MA
$66.97
Beta
0.68
Avg. Volume
2.69M
EPS (Annual)
$3.43
P/B
15.71
Rev/Employee
$2.9M
Loading...
Loading...
News
all
press releases
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) COO Sells 4,263 Shares of Stock
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) COO Cortney Caudill sold 4,263 shares of Halozyme Therapeutics stock in a transaction dated Saturday, November 1st. The shares were sold at...
MarketBeat·4h ago
News Placeholder
More News
News Placeholder
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·13h ago
News Placeholder
Halozyme Therapeutics' (HALO) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a report on Friday...
MarketBeat·15h ago
News Placeholder
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Zacks·1d ago
News Placeholder
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B PR Newswire VANCOUVER, BC, Dec. 16, 2025 Issued on...
PR Newswire·3d ago
News Placeholder
Halozyme Therapeutics, Inc. $HALO Shares Bought by HRT Financial LP
HRT Financial LP lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 576.1% in the second quarter, according to its most recent filing with the Securities and Exchange...
MarketBeat·6d ago
News Placeholder
BI Asset Management Fondsmaeglerselskab A S Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO
BI Asset Management Fondsmaeglerselskab A S grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 19.1% during the second quarter, according to its most recent 13F filing...
MarketBeat·7d ago
News Placeholder
Marshall Wace LLP Has $20.24 Million Holdings in Halozyme Therapeutics, Inc. $HALO
Marshall Wace LLP trimmed its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.1% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·11d ago
News Placeholder
2Xideas AG Sells 62,256 Shares of Halozyme Therapeutics, Inc. $HALO
2Xideas AG reduced its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 25.2% during the second quarter, according to its most recent filing with the SEC. The fund owned 184,546...
MarketBeat·11d ago
News Placeholder
Jim Lang Elected to Halozyme's Board of Directors
Jim Lang Elected to Halozyme's Board of Directors Jim Lang Elected to Halozyme's Board of Directors PR Newswire SAN DIEGO, Dec. 8, 2025 SAN DIEGO, Dec. 8, 2025 /PRNewswire/ -- Halozyme Therapeutics...
PR Newswire·11d ago
<
1
2
...
>

Latest HALO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.